Imugene Ltd (IMU AU) shares faced panic-selling after the announcement of termination of the company’s supply contract with Merck. However, the study will continue with alternative supply arrangement.
Recently, Imugene published a letter to the shareholders describing the strength and near-term catalyst of the company, which provided some respite to the stock.
Overall, Imugene, with a cash balance of A$109 million, is well-funded to advance its unique immune-oncology pipeline toward commercial success.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.